Curaleaf Escalates Hostile Bid War, Rebuts Aurora's Engagement Claims
CURLF sits 80% above its 52-week low of $5.4.
Summary
Curaleaf issued a point-by-point rebuttal to Aurora Cannabis' latest statements, revealing new financial deterioration at Aurora and rejecting claims of constructive engagement in the hostile takeover battle.
Key Events · M&A and Partnerships · CURLF
-
Curaleaf Rebuts Aurora's Engagement Claims
Curaleaf states no substantive deal conversations have occurred, and Aurora refused to sign an NDA or allow a site visit despite claiming to be 'open' to engagement.
-
Aurora's June Quarter Financials Deteriorated
Curaleaf discloses Aurora's June quarter adjusted EBITDA was 63% lower than March quarter, with negative operating cash flow of C$4.4 million and international revenue down approximately C$5 million month-over-month.
-
Aurora's Fiscal 2027 Guidance Points to Shrinking Business
Curaleaf claims Aurora is guiding to revenue approaching fiscal 2025 levels, adjusted gross margins declining from ~64% to mid-to-high 50% range, and lower Adjusted EBITDA.
-
Market Response Supports Curaleaf's Offer
Aurora's share price increased materially following the bid announcement and has traded near the implied value of Curaleaf's US$4.00 per share proposal.
Analysis · CURLF · Life Sciences
Curaleaf's latest 425 filing is a direct rebuttal to Aurora Cannabis' public statements, escalating the hostile takeover battle. The filing reveals new material details: Aurora's June quarter adjusted EBITDA fell 63% sequentially, operating cash flow was negative C$4.4 million, and international revenue declined C$5 million in a single month. Curaleaf also claims Aurora refused to sign an NDA or allow a site visit, contradicting Aurora's characterization of engagement. This matters because the credibility of Aurora's defense directly affects whether shareholders tender into Curaleaf's US$4.00 per share offer. The market has already responded favorably to the bid, with Aurora's stock trading near the implied offer value, but this rebuttal aims to further pressure Aurora's board to engage.
How filings like this one have moved
In the 30 days to Aug 25, 2026, 29.6% of the 2856 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.04%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CURLF was trading at $9.70 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $5.40 to $15.15. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.